The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II trial of maintenance oral metronomic vinorelbine versus close observation in advanced non-small cell lung cancer (NSCLC) following platinum-based chemotherapy: MA.NI.LA. trial.
 
Marco Platania
Research Funding - Pierre Fabre
 
Federico Nichetti
No Relationships to Disclose
 
Luca Porcu
No Relationships to Disclose
 
Felice Pasini
No Relationships to Disclose
 
Mattia Boeri
No Relationships to Disclose
 
Yasmina Modena
No Relationships to Disclose
 
Alessandro Del Conte
No Relationships to Disclose
 
Antonia Martinetti
No Relationships to Disclose
 
Elisa Sottotetti
No Relationships to Disclose
 
Daniele Pozzessere
No Relationships to Disclose
 
Emanuela Vattemi
No Relationships to Disclose
 
Francesco Verderame
No Relationships to Disclose
 
Luigi Cavanna
No Relationships to Disclose
 
Anna Paola Fraccon
No Relationships to Disclose
 
Barbara Formisano
No Relationships to Disclose
 
Rosaria Gallucci
No Relationships to Disclose
 
Giuseppe Lo Russo
No Relationships to Disclose
 
Valter Torri
No Relationships to Disclose
 
Filippo G. De Braud
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Dompè; Ignyta; Novartis; Pfizer; SERVIER; Tiziana Life Sciences
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; SERVIER
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Ignyta (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Nektar; Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche